MRx0518 is a single strain bacterial live biotherapeutic product taken from human faeces, which 4D said has been shown to stimulate the body's immune system in "a number" of pre-clinical cancer models.
After a successful development programme, 4D said it is now to start clinical studies in the
Chief Executive Duncan Peyton said: "This is a key step in the development of a true microbiome derived pharmaceutical product for the treatment of cancer. Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients.
"We look forward to reporting further progress as we move into the clinical phases of development of MRx0518."
Shares were up 6.3% in early trading on Wednesday at
